Eli Rosenbaum

8k citations
86 papers · 6.4k · 6 hit papers · h-index 40

Impact in

Papers in

Eli Rosenbaum

84 papers receiving 6.2k citations

Eli Rosenbaum's Hit Papers

Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial 2023 · 104 citations
1040+7+14Years since publication250500750

Peers

Eli Rosenbaum
Comparison fields: 5 of 104
  • Endocrinology, Diabetes and Metabolism 1.7k
  • Oncology 953
  • Pulmonary and Respiratory Medicine 1k
  • Otorhinolaryngology 176
  • Cancer Research 394
Replace Irvin D. Fleming with:
Irvin D. Fleming United States
Laura Deborah Locati Italy
Joel Jiang United States
Tawee Tanvetyanon United States
Catherine Lombard‐Bohas France
Alexandria T. Phan United States
Laura Williams Goff United States
Colin Hessel United States
Mark Agulnik United States
Jan Willem B. de Groot Netherlands
Eli Rosenbaum relative to Irvin D. Fleming United States Irvin D. Fleming's profile →
Citations per field
00.5×5×11×
Irvin D. Fleming · 1×
Citations per year

Countries citing papers authored by Eli Rosenbaum

Since Specialization
Citations

This map shows the geographic impact of Eli Rosenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Rosenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Rosenbaum more than expected).

Fields of papers citing papers by Eli Rosenbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Rosenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Rosenbaum. The network helps show where Eli Rosenbaum may publish in the future.

Co-authors

The 25 scholars most cited alongside Eli Rosenbaum, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eli Rosenbaum Line = papers co-authored together Eli Rosenbaum links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 86 papers — load more, or switch the sort, to bring in the rest.

#Work
1
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Hit paper breakdown →
2005846
2
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Hit paper breakdown →
2021490
3
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2020408
4
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Hit paper breakdown →
2019313
5 2004217
6 2006217
7 2006205
8 2005203
9 2004188
10 2006165
11 2004154
12 2017141
13
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
Hit paper breakdown →
2022138
14 2005132
15 2008125
16 2005117
17 2005113
18 2019113
19 2005111
20 2004109

About Eli Rosenbaum

Eli Rosenbaum is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism, Surgery, Molecular Biology and Otorhinolaryngology, having authored 86 papers that have together received 6.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (23 papers), Bladder and Urothelial Cancer Treatments (16 papers), Epigenetics and DNA Methylation (10 papers), Prostate Cancer Diagnosis and Treatment (9 papers), Thyroid Cancer Diagnosis and Treatment (8 papers), Renal cell carcinoma treatment (7 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Head and Neck Cancer Studies (4 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.7k citations), Oncology (953 citations), Pulmonary and Respiratory Medicine (1k citations), Otorhinolaryngology (176 citations) and Cancer Research (394 citations). Eli Rosenbaum has collaborated with scholars based in United States, Israel and Italy. Frequent co-authors include David Sidransky, William H. Westra, Mohammad Obaidul Hoque, Yoram Cohen, Shahnaz Begum, MARIANNA L. ZAHURAK, Rui Henrique, Ralph Patrick Tufano, Wim Van Criekinge and William H. Westra. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, The Lancet Oncology, The Journal of Urology and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact